A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.Susan M. Domchek, Robert H. Vonderheide, Andrew Hendifar et al.|Journal of Clinical Oncology|2014Cited by 3